切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2020, Vol. 09 ›› Issue (04) : 324 -328. doi: 10.3877/cma.j.issn.2095-3232.2020.04.007

所属专题： 文献；

临床研究

不同部位结肠癌肝转移临床病理特点及其术后预后影响因素分析
施长鹰1, 董志涛1, 廖博懿1, 乔亮1, 沈伟峰1, 杨甲梅1,†()   
  1. 1. 200438　上海东方肝胆外科医院特需一科
  • 收稿日期:2020-03-06 出版日期:2020-08-10
  • 通信作者: 杨甲梅

Clinicopathological characteristics of colon cancer in different sites with liver metastases and analysis of postoperative prognostic factors

Changying Shi1, Zhitao Dong1, Boyi Liao1, Liang Qiao1, Weifeng Shen1, Jiamei Yang1,†()   

  1. 1. Department of Special Treatment, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China
  • Received:2020-03-06 Published:2020-08-10
  • Corresponding author: Jiamei Yang
  • About author:
    Corresponding author: Yang Jiamei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

施长鹰, 董志涛, 廖博懿, 乔亮, 沈伟峰, 杨甲梅. 不同部位结肠癌肝转移临床病理特点及其术后预后影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 09(04): 324-328.

Changying Shi, Zhitao Dong, Boyi Liao, Liang Qiao, Weifeng Shen, Jiamei Yang. Clinicopathological characteristics of colon cancer in different sites with liver metastases and analysis of postoperative prognostic factors[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(04): 324-328.

目的

探讨不同部位结肠癌肝转移（CLM）临床病理特征及其术后影响因素。

方法

回顾性分析2009年1月至2015年6月在上海东方肝胆外科医院行肝部分切除的106例CLM患者临床资料。其中男64例，女42例；年龄33～70岁，中位年龄57岁。患者均签署知情同意书，符合医学伦理学规定。根据原发灶部位不同将患者分为左半结肠癌组（56例）和右半结肠癌组（50例），观察两组临床病理学差异和生存预后，分析CLM预后因素。率的比较采用χ2检验。单因素和生存分析采用Kaplan-Meier法和Log-rank检验。采用Cox回归分析影响预后的独立危险因素。

结果

左、右半结肠癌组发生淋巴结转移患者分别为20、29例，右半结肠癌组淋巴分期更晚（χ2=5.278，P<0.05）。左、右半结肠癌组中位总生存时间分别为55、44个月，右半结肠癌组预后更差（χ2=4.376，P<0.05）。单因素分析结果显示，年龄、CEA、原发灶位置、淋巴结转移、肝转移时间间隔、转移瘤数目、再复发后治疗反应为CLM患者术后总体生存的影响因素（χ2=3.941，6.194，4.376，4.355，7.106，6.550，7.250；P<0.05）。多因素分析显示，术前CEA水平≥200 μg/L、再复发后治疗非完全缓解是影响CLM患者术后总体生存的独立危险因素（HR=1.748，2.265；P<0.05）。

结论

原发灶位于右半结肠的CLM患者预后更差，CEA水平和再复发治疗反应是影响其远期预后的独立因素。

关键词: 结直肠肿瘤, 肿瘤转移, 肝切除术, 预后
Objective

To explore the clinicopathological characteristics of different sites colon cancer with liver metastasis (CLM) and their postoperative prognostic factors.

Methods

Clinical data of 106 patients with CLM who underwent partial liver resection from January 2009 to June 2015 at Shanghai Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. Among them, 64 were male and 42 female, aged 33-70 years and with a median of 57 years. The informed consents of all patients were obtained and the local ethical committee approval was received. Patients were assigned to left colon cancer group (n=56) and right colon cancer group (n=50) according to the different location of primary foci, and the clinicopathological difference and survival prognosis between two groups was observed. The prognostic factors of CLM were analyzed. Comparisons in rate were performed by Chi-square test. Univariate and survival analyses were performed using Kaplan-Meier method and Log-rank test. Independent risk factors for the prognosis were analyzed using Cox regression.

Results

There were 20 and 29 cases with lymph node metastasis in the left and right colon cancer groups, respectively, and the lymph node staging in right colon cancer group was more advanced (χ2=5.278, P<0.05). The median overall survival in the left and right colon cancer group was 55 and 44 months, respectively, and the right colon cancer group had poorer prognosis (χ2=4.376, P<0.05). Univariate analysis indicated that age, CEA, location of primary foci, lymphatic metastasis, time interval across liver metastases, number of metastases, and response to treatment after recurrence were the influencing factors for the postoperative overall survival of CLM patients (χ2=3.941, 6.194, 4.376, 4.355, 7.106, 6.550, 7.250; P<0.05). Multivariate analysis showed that preoperative CEA level ≥200 μg/L and incomplete remission to treatment after recurrence were the independent risk factors for postoperative overall survival in CLM patients (HR=1.748, 2.265; P<0.05).

Conclusions

CLM with the primary foci located in the right-sided colon has poorer prognosis. CEA levels and response to treatment after recurrence are the independent factors for long-term prognosis.

Key words: Colorectal neoplasms, Neoplasm metastasis, Hepatectomy, Prognosis
表1 左半结肠癌组和右半结肠癌组患者临床病理特征比较
组别 例数 性别（例） 年龄（岁，±s ） CEA（例） 原发瘤T分期（例） 原发瘤N分期（例） 肝转移间隔（例）
男 女 <200 μg/L ≥200 μg/L ≤12个月 ≤12个月 N0 N1、N2 ≤12个月 >12个月
左半结肠癌组 56 33 23 55±9 38 18 42 14 36 20 22 34
右半结肠癌组 50 31 19 56±9 31 19 33 17 21 29 28 22
统计值 ? χ2=0.104 t=-0.048 χ2=0.399 χ2=1.034 χ2=5.278 χ2=2.961
P值 ? 0.747 0.828 0.528 0.309 0.022 0.085
组别 例数 转移瘤最大径（cm，±s ） 转移瘤数量（例） 手术切缘（例） 分化程度（例） 新辅助化疗（例） 再复发后治疗反应（例）
单发 多发 R0 R1 低分化 中-高分化 无 有 完全缓解 非完全缓解
左半结肠癌组 56 4.4±1.3 28 28 35 21 33 18 45 11 11 38
右半结肠癌组 50 4.5±1.4 30 20 35 15 33 17 45 5 10 38
统计值 ? t=-0.765 χ2=1.066 χ2=0.663 χ2=0.041 χ2=1.917 χ2=0.037
P值 ? 0.384 0.302 0.416 0.839 0.166 0.847
图1 结肠癌肝转移患者术后总体生存Kaplan-Meier曲线
表2 106例结肠癌肝转移患者术后总体生存的单因素影响分析
因素 例数 中位生存时间（月） 95% CI χ2值 P值
性别 ? ? ? 1.575 0.209
? 男 64 48 41～55 ? ?
? 女 42 48 35～61 ? ?
年龄（岁） ? ? ? 3.941 0.047
? <65 87 51 42～60 ? ?
? ≥65 19 40 39～41 ? ?
CEA （μg/L） ? ? ? 6.194 0.013
? <200 69 56 48～65 ? ?
? ≥200 37 43 36～50 ? ?
原发灶位置 ? ? ? 4.376 0.036
? 左半结肠 56 55 47～63 ? ?
? 右半结肠 50 44 38～50 ? ?
T分期 ? ? ? 2.586 0.108
? T1/2 75 53 46～60 ? ?
? T3/4 31 42 39～45 ? ?
N分期 ? ? ? 4.355 0.037
? N0 57 56 48～64 ? ?
? N1/2 49 44 37～51 ? ?
肝转移时间间隔（月） ? ? ? 7.106 0.008
? >12 56 57 50～64 ? ?
? ≤12 50 41 36～46 ? ?
转移瘤数量 ? ? ? 6.550 0.010
? 单发 58 57 47～67 ? ?
? 多发 48 45 39～51 ? ?
转移瘤最大径（cm） ? ? ? 0.638 0.424
? <5 79 46 36～56 ? ?
? ≥5 27 51 45～57 ? ?
手术切缘 ? ? ? 0.172 0.679
? R0 70 48 39～57 ? ?
? R1 36 51 38～64 ? ?
分化程度 ? ? ? 1.404 0.236
? 低分化 71 48 43～53 ? ?
? 中-高分化 35 51 34～68 ? ?
新辅助化疗 ? ? ? 0.031 0.861
? 是 16 47 44～50 ? ?
? 否 90 51 41～62 ? ?
再复发后治疗反应 ? ? ? 7.250 0.007
? 完全缓解 21 60 47～73 ? ?
? 非完全缓解 76 44 40～48 ? ?
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca Cancer J Clin, 2018, 68(6): 394-424.
[2]
Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials[J]. JAMA Oncol, 2017, 3(2):194-201.
[3]
Modest DP, Stintzing S, von Weikersthal LF, et al. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)[J]. Oncotarget, 2017, 8(62):105749-105760.
[4]
Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer[J]. Ann Gastroenterol Surg, 2019, 3(1):50-56.
[5]
Oliveira RC, Alexandrino H, Cipriano MA, et al. Liver metastases and histological growth patterns: billogical behavior and potential clinical implications-another path to individualized medicine?[J].J Oncol, 2019:6280347.
[6]
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8): 1386-1422.
[7]
Mitchell D, Puckett Y, Nguyen QN. Literature review of current management of colorectal iver metastasis[J]. Cureus, 2019, 11(1):e3940.
[8]
Shin H, Kim CW, Lee JL, et al. Solitary colorectal liver metastasis after curative intent surgery: prognostic factors affecting outcomes and survival[J]. ANZ J Surg, 2019, 89(1/2):61-67.
[9]
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3):309-318.
[10]
蒋微琴，陈功．初始可切除的结直肠癌肝转移新辅助治疗的价值[J]．肝胆胰外科杂志，2019, 31(4):203-207.
[11]
裴谦，裴海平．结直肠癌肝转移疗效评价[J/CD]．中华肝脏外科手术学电子杂志，2019, 8(2):101-103.
[12]
Kamran SC, Clark JW, Zheng H, et al. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: results from a large retrospective cohort with mutational analysis[J]. Cancer Med, 2018, 7(7):2934-2942.
[13]
陈功．原发瘤部位在晚期结直肠癌整体诊疗策略中的价值[J/CD]．肿瘤综合治疗电子杂志，2017, 3(2):1-4.
[14]
Xie Y, Huang Y, Ruan Q, et al. Impact of tumor site on lymph node status and survival in colon cancer[J]. J Cancer, 2019, 10(11):2376-2383.
[15]
Prasanna T, Karapetis CS, Roder D, et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern[J]. Acta Oncol, 2018, 57(11):1438-1444.
[16]
Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features[J]. Ann Oncol, 2014, 25(10):1995-2001.
[17]
Mik M, Berut M, Dziki L, et al. Right- and left-sided colon cancer: clinical and pathological differences of the disease entity in one organ[J]. Arch Med Sci, 2017, 13(1):157-162.
[18]
Yang J, Du XL, Li ST, et al. Characteristics of differently located colorectal cancers support proximal and distal classification:a population-based study of 57,847 patients[J]. Plos One, 2016, 11(12):e0167540.
[19]
Hsu YL, Lin CC, Jiang JK, et al. Clinicopathological and molecular differences in colorectal cancer according to location[J]. Int J Biol Markers, 2019, 34(1): 47-53.
[20]
Sandhu J, Lavingia V, Fakih M. Systemic treatment for metastatic colorectal cancer in the era of precision medicine[J]. J Surg Oncol, 2019, 119(5):564-582
[1] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[8] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[9] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[10] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[11] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[12] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[13] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号